Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ISF 35

Next Previous
X
Search
Drug Profile

ISF 35

Alternative Names: Ad-CD154; Ad-ISF35; Ad-ISF35 transduced CLL B-cells; Adenovirus-CD 154; CD154-gene-therapy; Immune Stimulatory Factor 35; ISF-35; rAd.CD40L

Latest Information Update: 30 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memgen LLC
  • Developer Memgen; The Leukemia & Lymphoma Society; University of California, San Diego; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Gene therapies
  • Mechanism of Action CD40 ligand stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Malignant melanoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 30 Sep 2021 Discontinued - Phase-I for Chronic lymphocytic leukaemia (Combination therapy, Refractory metastatic disease) in USA (IV) (Memgen pipeline, September 2021)
  • 30 Sep 2021 Discontinued - Phase-II for Chronic lymphocytic leukaemia (Monotherapy) in USA (Intralymphatic) (Memgen pipeline, September 2021)
  • 30 Sep 2021 Discontinued - Phase-II for Non-Hodgkin's lymphoma (Monotherapy) in USA (Intralymphatic) (Memgen pipeline, September 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top